HRP20211243T1 - Metode liječenja raka uporabom 3-(4-((4-(morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-diona - Google Patents
Metode liječenja raka uporabom 3-(4-((4-(morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-diona Download PDFInfo
- Publication number
- HRP20211243T1 HRP20211243T1 HRP20211243TT HRP20211243T HRP20211243T1 HR P20211243 T1 HRP20211243 T1 HR P20211243T1 HR P20211243T T HRP20211243T T HR P20211243TT HR P20211243 T HRP20211243 T HR P20211243T HR P20211243 T1 HRP20211243 T1 HR P20211243T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- use according
- multiple myeloma
- cancer
- comprises administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (15)
1. Spoj za uporabu u metodi liječenja ili ovladavanja karcinomom kod pacijenta kojem je potrebno takvo liječenje ili ovladavanje, naznačen time što je spoj 3-(4-((4-(morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il) piperidin-2,6-dion sljedeće strukture:
[image]
ili njihov enantiomer ili smjesa enantiomera, ili njihova farmaceutski prihvatljiva sol, solvat, hidrat, kokristal, klatrat ili polimorf, i
pri čemu je rak mijelom ili limfom.
2. Spoj za uporabu u skladu s patentnim zahtjevom 1, naznačen time što je rak Hodgkinov limfom, ne-Hodgkinov limfom, kožni limfom T-stanica, kožni limfom B-stanica, difuzni limfom velikih B-stanica, folikularni limfom niskog stupnja, Waldenstromova makroglobulinemija, tinja mijelom ili indolentni mijelom.
3. Spoj za uporabu u skladu s patentnim zahtjevom 1, naznačen time što je rak multipli mijelom.
4. Spoj za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je rak relapsan ili refraktorni; proizvoljno pri čemu je rak otporan na lijekove.
5. Spoj za uporabu u skladu s patentnim zahtjevom 3, naznačen time što je multipli mijelom recidivan ili je refraktorrni multipli mijelom s oštećenom bubrežnom funkcijom.
6. Spoj za uporabu u skladu s patentnim zahtjevom 3, naznačen time što je multipli mijelom otporan na lijek na lenalidomid.
7. Spoj za uporabu u skladu s patentnim zahtjevom 1, naznačen time što metoda obuhvaća davanje navedenog spoja pacijentima s multiplim mijelomom prije, za vrijeme ili nakon transplantacije autologne matične stanice periferne krvi; ili gdje metoda obuhvaća davanje navedenog spoja pacijentima s relapsom multiplog mijeloma nakon transplantacije matičnih stanica.
8. Spoj za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što metoda nadalje obuhvaća davanje terapeutski učinkovite količine jedne ili više dodatnih aktivnih tvari, po želji je dodatno aktivno sredstvo odabrano iz skupine koju čine alkilirajuće sredstvo , analog adenozina, glukokortikoid, inhibitor kinaze, inhibitor SYK, inhibitor PDE3, inhibitor PDE7, doksorubicin, klorambucil, vinkristin, bendamustin, forskolin i rituksimab; po mogućnosti gdje je dodatno aktivno sredstvo rituksimab.
9. Spoj za uporabu prema zahtjevu 8, naznačen time, da je dodatno aktivno sredstvo deksametazon.
10. Spoj za uporabu u skladu s patentnim zahtjevom 9, naznačen time što metoda obuhvaća davanje navedenog spoja u kombinaciji s deksametazonom pacijentima s relapsom ili refraktornim multiplim mijelomom.
11. Spoj za uporabu u skladu s patentnim zahtjevom 9, naznačen time što metoda obuhvaća davanje navedenog spoja u kombinaciji s deksametazonom kao spasonosnu terapiju za pacijente s multiplim mijelomom nakon niskorizične transplantacije; ili gdje metoda obuhvaća davanje navedenog spoja u kombinaciji s deksametazonom kao terapiju održavanja pacijentima s multiplim mijelomom nakon transplantacije autologne koštane srži.
12. Spoj za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što 3- (4 - ((4- (morfolinometil) benzil) oksi) -1-oksoizoindolin-2-il) piperidin-2,6-dion, ili enantiomer ili njihova smjesa enantiomera, ili njihova farmaceutski prihvatljiva sol, solvat, hidrat, kokristal, klatrat ili polimorf, daje se u količini od oko 0,1 do oko 100 mg dnevno, po izboru u količini od oko 0.1 do oko 5 mg na dan ili u količini od oko 0.1, 0.2, 0.5, 1, 2, 2.5, 3, 4, 5, 7.5, 10, 15, 20, 25, 50 ili 100 mg dnevno, ili gdje se spoj daje oralno ili se daje u kapsuli ili tableti, po mogućnosti u 10 mg ili 25 mg kapsule.
13. Spoj za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što se spoj daje 21 dan, nakon čega slijedi sedam dana odmora u 28-dnevnom ciklusu.
14. Spoj za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što je spoj (S) -3-(4- ((4-(morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-dion.
15. Spoj za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što je spoj (S)-3-(4-((4-(morfolinometil)benzil)oksi)-1 oksoizoindolin-2-il) piperidin-2,6-dion hidroklorid.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261681447P | 2012-08-09 | 2012-08-09 | |
| US201261722727P | 2012-11-05 | 2012-11-05 | |
| EP13751007.9A EP2882442B1 (en) | 2012-08-09 | 2013-08-08 | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| PCT/US2013/054055 WO2014025960A1 (en) | 2012-08-09 | 2013-08-08 | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211243T1 true HRP20211243T1 (hr) | 2021-11-12 |
Family
ID=49004013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211243TT HRP20211243T1 (hr) | 2012-08-09 | 2013-08-08 | Metode liječenja raka uporabom 3-(4-((4-(morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-diona |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US20140045843A1 (hr) |
| EP (2) | EP2882442B1 (hr) |
| JP (2) | JP6347782B2 (hr) |
| KR (3) | KR102266510B1 (hr) |
| CN (4) | CN114366746A (hr) |
| AU (1) | AU2013299627C1 (hr) |
| BR (1) | BR112015002285B1 (hr) |
| CA (1) | CA2881116C (hr) |
| CY (1) | CY1124622T1 (hr) |
| DK (1) | DK2882442T3 (hr) |
| EA (1) | EA029485B1 (hr) |
| ES (1) | ES2881220T3 (hr) |
| HK (1) | HK1211489A1 (hr) |
| HR (1) | HRP20211243T1 (hr) |
| HU (1) | HUE056127T2 (hr) |
| IL (3) | IL288506B2 (hr) |
| IN (1) | IN2015DN00886A (hr) |
| LT (1) | LT2882442T (hr) |
| MX (1) | MX367869B (hr) |
| NI (1) | NI201500012A (hr) |
| NZ (1) | NZ628078A (hr) |
| PH (1) | PH12015500212A1 (hr) |
| PL (1) | PL2882442T3 (hr) |
| PT (1) | PT2882442T (hr) |
| RS (1) | RS62201B1 (hr) |
| SG (3) | SG10202108516PA (hr) |
| SI (1) | SI2882442T1 (hr) |
| SM (1) | SMT202100457T1 (hr) |
| TW (2) | TWI723266B (hr) |
| UA (1) | UA116544C2 (hr) |
| WO (1) | WO2014025960A1 (hr) |
| ZA (1) | ZA201500564B (hr) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5645816B2 (ja) | 2009-05-25 | 2014-12-24 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
| US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| ES2956743T3 (es) | 2010-02-11 | 2023-12-27 | Celgene Corp | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos de uso de los mismos |
| US9056852B2 (en) | 2011-03-28 | 2015-06-16 | Mei Pharma, Inc. | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
| ES3013301T3 (en) | 2012-06-29 | 2025-04-11 | Celgene Corp | Methods for determining drug efficacy using ikzf3 (aiolos) |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| BR112015005243A2 (pt) * | 2012-09-10 | 2017-07-04 | Celgene Corp | métodos para o tratamento de câncer de mama localmente avançado |
| US9695145B2 (en) | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| US20160313300A1 (en) | 2013-12-06 | 2016-10-27 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| JP6640126B2 (ja) | 2014-06-27 | 2020-02-05 | セルジーン コーポレイション | セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法 |
| JP2017538104A (ja) * | 2014-10-07 | 2017-12-21 | セルジーン コーポレイション | 癌治療に対する臨床的感応性を予測するためのバイオマーカーの使用 |
| EP3352756A1 (en) * | 2015-09-25 | 2018-08-01 | Celgene Corporation | Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| KR102002581B1 (ko) * | 2016-10-04 | 2019-07-22 | 주식회사 종근당 | 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물 |
| US20180238886A1 (en) * | 2017-01-31 | 2018-08-23 | Celgene Corporation | Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds |
| AU2018269982B2 (en) * | 2017-05-16 | 2024-06-13 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating cancer with atypical BRAF mutations |
| KR20200009088A (ko) | 2017-05-23 | 2020-01-29 | 메이 파마, 아이엔씨. | 병용 요법 |
| WO2019006299A1 (en) * | 2017-06-30 | 2019-01-03 | Celgene Corporation | COMPOSITIONS AND METHODS FOR THE USE OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE |
| WO2019014100A1 (en) * | 2017-07-10 | 2019-01-17 | Celgene Corporation | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF |
| MA49921A (fr) | 2017-08-14 | 2021-05-12 | Mei Pharma Inc | Polythérapie |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| WO2019084434A1 (en) | 2017-10-26 | 2019-05-02 | National University Of Singapore | NEW APPROACH FOR UNIVERSAL MONITORING OF MINIMUM RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| AU2019321526A1 (en) * | 2018-08-14 | 2021-03-25 | Mei Pharma, Inc. | Treatment of relapsed follicular lymphoma |
| KR102605291B1 (ko) * | 2018-09-07 | 2023-11-23 | 메드샤인 디스커버리 아이엔씨. | 트리사이클릭 퓨란에 의해 치환된 피페리디온 화합물 |
| MX2021003842A (es) * | 2018-10-01 | 2021-05-27 | Celgene Corp | Terapia combinada para el tratamiento del cancer. |
| US12263190B2 (en) | 2018-11-08 | 2025-04-01 | Juno Therapeutics, Inc. | Methods and combinations for treatment and T cell modulation |
| CN113423427A (zh) | 2018-11-30 | 2021-09-21 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| BR112021019748A2 (pt) | 2019-04-05 | 2021-12-07 | Kymera Therapeutics Inc | Degradadores de stat e usos dos mesmos |
| AR119715A1 (es) * | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| EA039874B1 (ru) * | 2019-06-06 | 2022-03-22 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно) |
| CN114980918A (zh) | 2019-11-07 | 2022-08-30 | 朱诺治疗学股份有限公司 | T细胞疗法与(s)-3-[4-(4-吗啉-4-基甲基-苄氧基)-1-氧代-1,3-二氢-异吲哚-2-基]-哌啶-2,6-二酮的组合 |
| BR112022010537A2 (pt) | 2019-12-02 | 2022-08-16 | Celgene Corp | Terapia para o tratamento do câncer |
| AU2020412780A1 (en) | 2019-12-23 | 2022-07-21 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| US20240424110A1 (en) | 2020-03-19 | 2024-12-26 | Kymera Therapeutics, Inc. | Mdm2 degraders and uses thereof |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| KR20230027082A (ko) * | 2020-06-25 | 2023-02-27 | 셀진 코포레이션 | 조합 요법을 사용한 암의 치료 방법 |
| CA3202360A1 (en) | 2020-12-30 | 2022-07-07 | Nello Mainolfi | Irak degraders and uses thereof |
| CA3207049A1 (en) | 2021-02-15 | 2022-08-18 | Jared Gollob | Irak4 degraders and uses thereof |
| CN117715904A (zh) | 2021-05-07 | 2024-03-15 | 凯麦拉医疗公司 | Cdk2降解剂和其用途 |
| KR20240110592A (ko) | 2021-10-29 | 2024-07-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak4 분해제 및 이의 합성 |
| US12091411B2 (en) | 2022-01-31 | 2024-09-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2024015618A2 (en) * | 2022-07-15 | 2024-01-18 | St. Jude Children's Research Hospital, Inc. | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione/2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione analogs as modulators of cereblon protein |
| WO2024064646A1 (en) | 2022-09-20 | 2024-03-28 | Celgene Corporation | Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same |
| WO2025076472A1 (en) | 2023-10-06 | 2025-04-10 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025120113A1 (en) | 2023-12-08 | 2025-06-12 | Celgene Corporation | Therapy for the treatment of multiple myeloma |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| CA2418835A1 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| AU2002256371B2 (en) | 2001-04-26 | 2008-01-10 | Amgen Mountain View Inc. | Combinatorial libraries of monomer domains |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| CA2587424A1 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
| US20080051379A1 (en) | 2004-12-01 | 2008-02-28 | Trustees Of Boston University | Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms |
| ES2601131T3 (es) * | 2007-03-20 | 2017-02-14 | Celgene Corporation | Derivados de isoindolina 4'-O-sustituidos y composiciones que los comprenden y métodos de uso de los mismos |
| JP5645816B2 (ja) | 2009-05-25 | 2014-12-24 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
| ES2956743T3 (es) | 2010-02-11 | 2023-12-27 | Celgene Corp | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos de uso de los mismos |
| KR20130038838A (ko) * | 2010-03-12 | 2013-04-18 | 셀진 코포레이션 | 레날리도미드, 및 예측 인자로서 유전자 및 단백질 바이오마커를 사용한 비호지킨 림프종의 치료 방법 |
| SG192947A1 (en) * | 2011-03-11 | 2013-09-30 | Celgene Corp | Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases |
-
2013
- 2013-08-08 HU HUE13751007A patent/HUE056127T2/hu unknown
- 2013-08-08 CN CN202110936758.6A patent/CN114366746A/zh active Pending
- 2013-08-08 RS RS20210904A patent/RS62201B1/sr unknown
- 2013-08-08 EA EA201590345A patent/EA029485B1/ru not_active IP Right Cessation
- 2013-08-08 US US13/962,776 patent/US20140045843A1/en not_active Abandoned
- 2013-08-08 MX MX2015001775A patent/MX367869B/es active IP Right Grant
- 2013-08-08 ES ES13751007T patent/ES2881220T3/es active Active
- 2013-08-08 PL PL13751007T patent/PL2882442T3/pl unknown
- 2013-08-08 TW TW107117959A patent/TWI723266B/zh active
- 2013-08-08 UA UAA201501971A patent/UA116544C2/uk unknown
- 2013-08-08 KR KR1020207023283A patent/KR102266510B1/ko active Active
- 2013-08-08 CA CA2881116A patent/CA2881116C/en active Active
- 2013-08-08 CN CN202110938460.9A patent/CN114344307A/zh active Pending
- 2013-08-08 CN CN201711401933.1A patent/CN108245518B/zh active Active
- 2013-08-08 DK DK13751007.9T patent/DK2882442T3/da active
- 2013-08-08 IN IN886DEN2015 patent/IN2015DN00886A/en unknown
- 2013-08-08 WO PCT/US2013/054055 patent/WO2014025960A1/en active Application Filing
- 2013-08-08 AU AU2013299627A patent/AU2013299627C1/en active Active
- 2013-08-08 KR KR1020217018115A patent/KR102414005B1/ko active Active
- 2013-08-08 SM SM20210457T patent/SMT202100457T1/it unknown
- 2013-08-08 CN CN201380052496.0A patent/CN104837491A/zh active Pending
- 2013-08-08 TW TW102128576A patent/TWI653977B/zh active
- 2013-08-08 HR HRP20211243TT patent/HRP20211243T1/hr unknown
- 2013-08-08 JP JP2015526690A patent/JP6347782B2/ja active Active
- 2013-08-08 SG SG10202108516PA patent/SG10202108516PA/en unknown
- 2013-08-08 EP EP13751007.9A patent/EP2882442B1/en active Active
- 2013-08-08 HK HK15112438.8A patent/HK1211489A1/xx unknown
- 2013-08-08 IL IL288506A patent/IL288506B2/en unknown
- 2013-08-08 SI SI201331908T patent/SI2882442T1/sl unknown
- 2013-08-08 EP EP21177385.8A patent/EP3949968A1/en active Pending
- 2013-08-08 LT LTEPPCT/US2013/054055T patent/LT2882442T/lt unknown
- 2013-08-08 PT PT137510079T patent/PT2882442T/pt unknown
- 2013-08-08 KR KR1020157006019A patent/KR102146848B1/ko active Active
- 2013-08-08 SG SG11201500998QA patent/SG11201500998QA/en unknown
- 2013-08-08 SG SG10201701057SA patent/SG10201701057SA/en unknown
- 2013-08-08 BR BR112015002285-5A patent/BR112015002285B1/pt active IP Right Grant
- 2013-08-08 NZ NZ628078A patent/NZ628078A/en unknown
-
2015
- 2015-01-26 ZA ZA2015/00564A patent/ZA201500564B/en unknown
- 2015-01-29 IL IL237013A patent/IL237013B/en active IP Right Grant
- 2015-01-30 PH PH12015500212A patent/PH12015500212A1/en unknown
- 2015-02-06 NI NI201500012A patent/NI201500012A/es unknown
-
2016
- 2016-05-13 US US15/154,838 patent/US20160256468A1/en not_active Abandoned
-
2018
- 2018-02-02 JP JP2018017168A patent/JP2018100276A/ja not_active Withdrawn
-
2019
- 2019-08-01 US US16/529,233 patent/US20190388429A1/en not_active Abandoned
-
2020
- 2020-07-27 IL IL276319A patent/IL276319B/en unknown
-
2021
- 2021-07-16 CY CY20211100645T patent/CY1124622T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211243T1 (hr) | Metode liječenja raka uporabom 3-(4-((4-(morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-diona | |
| AU2020201321B2 (en) | Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| KR20210095118A (ko) | Cxcr4 억제제의 조성물 및 제조 방법 및 용도 | |
| US8557847B2 (en) | Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor | |
| US20090149511A1 (en) | Administration of an Inhibitor of HDAC and an mTOR Inhibitor | |
| AR070299A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas, usos y composiciones farmaceuticas | |
| CA2725390C (en) | Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer | |
| JP2010509370A (ja) | 癌の治療用のＥＲα＋リガンドとヒストンデアセチラーゼ阻害剤との組み合わせ | |
| EP1863485A2 (en) | Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions | |
| EP3698790A1 (en) | Methods and compositions for treating abnormal cell growth | |
| WO2009126537A1 (en) | Administration of an inhibitor of hdac and an hmt inhibitor | |
| JP2017525713A5 (hr) | ||
| AR068947A1 (es) | Inhibidor de la proteina activadora de la 5- lipoxigenasa (flap), composiciones farmaceuticas, sales y solvatos | |
| US20150005262A1 (en) | Hypoxia activated prodrugs and mtor inhibitors for treating cancer | |
| WO2018091999A1 (en) | Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer | |
| JP2020515600A (ja) | 抗がん併用療法 | |
| BRPI0921097B8 (pt) | composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto | |
| MX2011011058A (es) | Antagonistas del receptor ep4 para el tratamiento de cancer. | |
| EP2722042A4 (en) | INDANO DERIVATIVES, PHARMACEUTICALLY ALLOWED SALTS OR OPTICAL ISOMERS THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREFORE AS AN ACTIVE AGENT FOR THE PREVENTION OR TREATMENT OF VIRUS DISEASES | |
| JP2016199578A (ja) | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 | |
| BR112012016128A8 (pt) | Agente terapêutico (y-39983) para disfunção endotelial da córnea | |
| JP2025500826A (ja) | 慢性腎疾患を処置するためのアルドステロンシンターゼ阻害薬 | |
| US9233109B2 (en) | Compositions, methods of use, and methods of treatment | |
| EP4069231B1 (en) | Combinations of masupirdine with donepezil or memantine for treating behavioral and psychological symptoms in patients with dementia | |
| HK40053051A (en) | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer |